European Medicines Agency (EMA) review finds risks of Ingenol mebutate (Picato) for actinic keratosis outweigh benefits
Review compared Picato with imiquimod. After 3 years, 6.3% of patients treated with Picato (15/240) developed skin cancer, particularly squamous cell carcinoma, in the treated skin area vs. 2% of imiquimod patients (5/244 patients).
Source:
European Medicines Agency
SPS commentary:
Picato is no longer authorised in the EU as the marketing authorisation was withdrawn on 11 February 2020 at the request of the company that marketed the medicine.